Stephen T. Gately
Vorstandsvorsitzender bei Translational Drug Development LLC
Profil
Stephen T.
Gately was the founder of Silamed, Inc. which was founded in 2003, where he held the title of Chief Scientific Officer from 2003 to 2010.
Currently, he is the President & Chief Executive Officer at Translational Drug Development LLC since 2006.
Dr. Gately's former positions include being a Principal at Pfizer Inc., NeoPharm, Inc., and Northwestern University, and being a Chief Scientific Officer at TGen Drug Development Services.
Dr. Gately received a doctorate degree from McGill University.
Aktive Positionen von Stephen T. Gately
| Unternehmen | Position | Beginn |
|---|---|---|
Translational Drug Development LLC
 Translational Drug Development LLC Miscellaneous Commercial ServicesCommercial Services Translational Drug Development LLC engages in the provision of innovative services for oncology-focused companies. It offers preclinical, bioanalytical, regulatory, and clinical services. The company was founded in 2003 and is headquartered in Scottsdale, AZ. | Vorstandsvorsitzender | 01.03.2006 |
Ehemalige bekannte Positionen von Stephen T. Gately
| Unternehmen | Position | Ende |
|---|---|---|
| PFIZER, INC. | Corporate Officer/Principal | - |
Northwestern University
 Northwestern University Other Consumer ServicesConsumer Services Northwestern University is a private institution founded in 1851 to serve the Northwest Territory, an area that now includes the states of Ohio, Indiana, Illinois, Michigan, Wisconsin and parts of Minnesota. Northwestern has three campuses | Corporate Officer/Principal | - |
NeoPharm, Inc.
 NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | Corporate Officer/Principal | - |
Takeda Pharmaceuticals U.S.A., Inc.
 Takeda Pharmaceuticals U.S.A., Inc. Pharmaceuticals: MajorHealth Technology Takeda Pharmaceuticals U.S.A., Inc. develops and markets pharmaceutical products. It offers metabolic and cardiovascular, respiratory and immunology, central nervous system, oncology, and general medicine products. The company was founded in 1998 and is headquartered in Deerfield, IL. | Corporate Officer/Principal | - |
| TGen Drug Development Services | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Stephen T. Gately
| McGill University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| PFIZER, INC. | Health Technology |
| Private Unternehmen | 5 |
|---|---|
Silamed, Inc.
 Silamed, Inc. Pharmaceuticals: MajorHealth Technology Silamed, Inc. manufactures and markets pharmaceutical products. Its products include Silexyn, a silicon medicinal drug for cancer treatment and silicon derivatives. The firm offers drug discovery and development and non-oncology applications development services. The company was founded by Stephen T. Gatley and Stephen P. Wanaski in 2003 and is headquartered in Scottsdale, AZ. | Health Technology |
| TGen Drug Development Services | |
Takeda Pharmaceuticals U.S.A., Inc.
Takeda Pharmaceuticals U.S.A., Inc. Pharmaceuticals: MajorHealth Technology Takeda Pharmaceuticals U.S.A., Inc. develops and markets pharmaceutical products. It offers metabolic and cardiovascular, respiratory and immunology, central nervous system, oncology, and general medicine products. The company was founded in 1998 and is headquartered in Deerfield, IL. | Health Technology |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | Health Technology |
Translational Drug Development LLC
Translational Drug Development LLC Miscellaneous Commercial ServicesCommercial Services Translational Drug Development LLC engages in the provision of innovative services for oncology-focused companies. It offers preclinical, bioanalytical, regulatory, and clinical services. The company was founded in 2003 and is headquartered in Scottsdale, AZ. | Commercial Services |
